Latest News

Highs and lows for Fresenius Medical Care

Fresenius headquarters Bad Homburg, Germany
Fresenius headquarters in Bad Homburg, Germany


by um

Dialysis product and service provider Fresenius Medical Care has placed €500m notes. Yesterday, the medtech giant had to come to terms with a sharp drop in share price.

The notes, which have an with an aggregate principal amount of €500m, have a maturity of 7 years and an annual coupon of 1.5%. The issue price is 99.704% and the resulting yield amounts to 1.545%. FMC said in a statement that the transaction was very well received by investors and substantially oversubscribed. The proceeds will be used for general corporate purposes, including the refinancing of upcoming maturities. The notes the company placed today have a maturity of 7 years and an annual coupon of 1.5%. The issue price is 99.704% and the resulting yield amounts to 1.545%. 

FMC has applied to the Luxembourg Stock Exchange to admit the notes to trading on its regulated market.

On Wednesday, the Fresenius Medical Care share price took a sharp downward turn, going down to 82.76 from 85.60 a day earlier. With a loss of 3.4%, the Bavarian dialysis specialist was the biggest loser on the German exchange DAX. The reason: an analysis by Credit Suisse predicting difficulties ahead for the company due to rising wage pressure in the US.

Zelluna Immunotherapy and Glycostem Therapeutics in licence deal

TCR cell therapy specialist Zelluna Immunotherapy (Oslo) and NK cell manufacturing specialist Glycostem Therapeutics BV (Oss) have entered into a...

ADC Therapeutics enters licence option deal with Avacta Group

Under the terms of the agreement, Avacta Group (Cambridge, UK) will provide three small Affimer proteins designed to bind to undisclosed cancer...

Spanish sector attracting more and more investment

According to Spain's biotech association, the investor day attracted 60 investors from nine countries and provided more than 500 partnering...

Abcam buys Expedeon’s immunology business

“This purchase price is equivalent to twice Expedeon’s current market capitalisation or excess of 9-times 2018 annual group revenue,” the company...

Novo Nordisk enters haemophilia gene therapy field

Changes in the treatment standard of haemophilia A, such as Roche’s 2017 launch of Hemlibra, have put Novo Nordisk’s revenues (in the US$15.8bn...

Successful EFIB in Brussels

More than 260 companies with 480 delegates from 30 countries joined for this year’s “European Forum for industrial Biotechnology and Bioeconomy”...

€7.34m for cancer vaccine developer

Private clinical-stage biotech MaxiVAX announced that it has been awarded a European Commission grant of €2,785,000, thanks to the Horizon 2020 EIC...